No Flush Niacin 640 mg by Life Extension — Ingredients, Evidence & Safety

Product Label

📄 Open Full PDF View on NIH DSLD →

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Safety Alerts

⚠️ Niacin: 640mg is 18.3× the Tolerable Upper Intake Level (35mg)

Label Data

1 Capsule(s) Serving Size

100 Servings

Other Combinations Product Type

100% Evidence Coverage

Supplement Facts — Evidence Check

Niacin

640 mg NE (4000% DV)

⚠️ Exceeds Tolerable Upper Intake Level by 18.3× (UL: 35 mg) 📚 193 studies (Tier A: 5, B: 63)

RDA 14mg This product: 640mg UL 35mg

Inositol

160 mg

📊 Market median: 550.0mg (217 products) 📚 29 studies (Tier A: 0, B: 5)

This product: 160mg

Other Ingredients

Gelatin Stearate

Label Claims — Verification

❓ Nutrient

❓ All Other

❓ Structure/Function

All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years) Gluten Free

Product Information

📋 Directions for Use

Directions: Take one (1) capsule with food, or as recommended by a healthcare practitioner.

⚠️ Warnings & Precautions

Warnings: Keep out of reach of children.

Do not exceed recommended dose. Do not purchase if outer seal is broken or damaged.

When using nutritional supplements, please consult with your physician if you are undergoing treatment for a medical condition or if you are pregnant or lactating.

To report a serious adverse event or obtain product information, contact 1-866-280-2852.

Read the entire label and follow the directions carefully prior to use.

🧪 Formulation Notes

Gluten Free Non GMO LE Certified

Niacin activity without the characteristic flush

Additional Information

Scan for product info

Store tightly closed in a cool, dry place.

Non GMO LE Certified

Product Details

UPC / SKU 7 37870 37310 0

DSLD Entry Date 2025-05-21

Product Type Other Combinations

Form Capsule

Brand Life Extension

DSLD ID 328602

Data Updated 2026-04-11

Research Evidence

241 Research Sources

55 Avg Quality Score

113 Meta Analysis

75 Systematic Review

32 Rct

11 Clinical Trial

3 Other

3 Regulatory Source

1 Cochrane Review

1 Narrative Review

1 Openfda Safety

A Niacin for primary and secondary prevention of cardiovascular events

Meta Analysis The Cochrane database of systematic reviews 2017

PubMed DOI Cochrane

A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases

Meta Analysis BMJ (Clinical research ed.) 2013

PubMed DOI

A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients

Meta Analysis BMJ (Clinical research ed.) 2014

PubMed DOI

A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk

Meta Analysis Nature medicine 2024

PubMed DOI

A Meta-analysis and imputation refines the association of 15q25 with smoking quantity

Meta Analysis Nature genetics 2010

PubMed DOI

A Genome-wide meta-analyses identify multiple loci associated with smoking behavior

Meta Analysis Nature genetics 2010

PubMed DOI

A Antidepressants for smoking cessation

Meta Analysis The Cochrane database of systematic reviews 2014

PubMed DOI

A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne

Meta Analysis The Cochrane database of systematic reviews 2020

PubMed DOI Cochrane

B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis

Meta Analysis JAMA network open 2019

PubMed DOI

B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis

Meta Analysis JAMA 2016

PubMed DOI

View all evidence for Niacin →